RG-4733: all 33 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas CancerCompletedNCT01232829Phase 2Results posted
- RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
- Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate CancerTerminatedNCT01200810Phase 2Results posted
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedNCT01196416Phase 1/2Results posted
- RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line ChemotherapyTerminatedNCT01193868Phase 2Results posted
- RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
- RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01175343Phase 2Results posted
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedNCT01151449Phase 2Results posted
- A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) TherapyCompletedNCT01141569Phase 2Results posted
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedNCT01120275Phase 2Results posted
- RO4929097 in Treating Patients With Metastatic Colorectal CancerCompletedNCT01116687Phase 2Results posted
- Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal CancerWithdrawnNCT01270438Phase 2
- RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
- RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT01251172Phase 2
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast CancerTerminatedNCT01238133Phase 1
- RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell LeukemiaWithdrawnNCT01236586Phase 1
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid TumorsCompletedNCT01218620Phase 1
- RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by SurgeryWithdrawnNCT01216787Phase 2
- RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast CancerTerminatedNCT01208441Phase 1
- Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal CancerTerminatedNCT01198535Phase 1
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsCompletedNCT01198184Phase 1
- RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT01193881Phase 1
- RO4929097 Before Surgery in Treating Patients With Pancreatic CancerTerminatedNCT01192763Phase 1
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerTerminatedNCT01149356Phase 1
- Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01145456Phase 1
- Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
- RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
- Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid MalignanciesCompletedNCT01096355Phase 1
- Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
- RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By SurgeryTerminatedNCT01071564Phase 1
- An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung CancerCompletedNCT01070927Phase 2
- A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.CompletedNCT00532090Phase 1